Skip to content
2000
Volume 23, Issue 16
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Introduction: Small cell lung cancer (SCLC) is featured by a high TP53 mutant rate. Our previous research found that arsenic trioxide (AsO) could significantly inhibit the growth and metastasis of SCLC. Studies have shown that the degradation of mutant p53 mediated by murine double minute 2 (MDM2) can be induced by AsO, which probably contributes to the inhibition of SCLC, but the detailed mechanism is still unclear. We aimed to testify that AsO can inhibit the growth of SCLC cells by degrading mutant p53 protein via binding to MDM2. Methods: CCK-8 assay, cell cycle analysis, and western blot of apoptosis markers were used to evaluate the inhibitory effect of AsO on NCI-H446 cells (containing mutant p53) and NCI-H1299 cells (p53 null). The effects of AsO on p53 and its downstream proteins were identified by western blot using mut-p53-knockdown and overexpressed cell models. MDM2-knockdown cell models were constructed, and western blot, co-IP of mut-p53, and ubiquitin were carried out to explore the mediating effect of MDM2 in AsO induced mut-p53 degradation. Results: AsO inhibited proliferation and induced cell cycle arrest and apoptosis of SCLC cells in a dose- and timedependent manner. After mut-p53 knockdown or overexpressed, the inhibitory effect of AsO was dampened or enhanced. Additionally, AsO-induced mut-p53 ubiquitination was significantly weakened after MDM2 knockdown. Conclusion: AsO could inhibit SCLC cells by inhibiting proliferation and inducing cell cycle arrest and apoptosis. These inhibitory effects were achieved at least in part by upregulating MDM2, which, in turn, promotes ubiquitination and degradation of mut-p53.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520623666230530095435
2023-10-01
2025-03-15
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520623666230530095435
Loading

  • Article Type:
    Research Article
Keyword(s): Arsenic trioxide; As2O3; MDM2; p53; SCLC; small cell lung cancer
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test